Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Vaccine 219

Vaccine Vaccination Development Clinical Trials 219

Bio Pharma Dive

JUNE 13, 2025

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.

Medicine 161

Medicine Development Drugs 161

STAT News

JUNE 13, 2025

Congress is floating a 40% cut to the National Science Foundation and deep reductions to the National Institutes of Health — America’s two flagship research engines. The justification? A $2 trillion deficit. But cutting science to fix the deficit is like burning your seed corn because you’re low on groceries. It’s fiscally shortsighted and strategically self-defeating.

Engineer 119

Engineer Research 119

Scienmag

JUNE 13, 2025

Singapore – Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based method called “Fragle” that makes tracking cancer easier and faster using blood tests. Requiring only a small blood sample, this method analyses the size of DNA fragments in the blood to reveal distinct patterns that differentiate cancer DNA from healthy DNA, helping doctors track cancer treatment response more accurately and frequently.

DNA 59

DNA Genomics Genome Genetics 59

Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group

Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.

Compliance

ACRP blog

JUNE 13, 2025

The U.S. Food and Drug Administration’s (FDA’s) recent launch of an agency-wide large language model–powered artificial intelligence (AI) tool known Elsa and ongoing efforts to have another AI tool known as CDRH-GPT in place for speeding up reviews and approvals of medical devices by the end of June have attracted their share of both supporters and detractors.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Clinical Research 93

Scienmag

JUNE 13, 2025

image: Dr. Ravindra Uppaluri, director of Head and Neck Surgical Oncology at Dana-Farber and Brigham and Women’s Hospital view more Credit: Courtesy of Dana-Farber Cancer Institute BOSTON, June 13, 2025 — Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an

FDA Approval 59

FDA Approval Research Clinical Trials Clinical Trials 59

Scienmag

JUNE 13, 2025

Blood vessels are essential to nearly all tissues, delivering nutrients and oxygen, regulating hemostasis, and modulating inflammation. Recreating functional vascular networks is foundational to both basic and translational vascular biology, however current methods to make blood vessels from stem cells are often slow, inefficient, or lack the complexity needed for therapy.

Life Science 59

Life Science Research Development Engineer 59

The Pharma Data

JUNE 13, 2025

Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Clinical Results in Large B-Cell Lymphoma Johnson & Johnson recently presented promising first-in-human data from its ongoing Phase 1b study evaluating JNJ-90014496 (JNJ-4496) — an investigational, dual-targeting, autologous chimeric antigen receptor (CAR) T-cell therapy — in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not previously received a CAR T-cell therapy.

Clinical Development 40

Clinical Development Trials Development Protein 40

World of DTC Marketing

JUNE 13, 2025

What are FDA staffers thinking? In recent months, Kennedy’s involvement in high-level decisions—especially those seen as overly friendly to industry interests—has become a growing concern. And while the outside world may only see the final decisions and policy announcements, it’s the rank-and-file FDA staffers who live with the day-to-day fallout.

Doctor 157

Doctor Doctors Scientist Regulation 157

Bio Pharma Dive

JUNE 13, 2025

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an obesity medication that works differently than its popular Wegovy.

Trials 177

Trials Drugs 177

Advertisement

Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness

Trials

The Pharma Data

JUNE 13, 2025

FDA Approves KEYTRUDA® (Pembrolizumab) for Perioperative Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Merck known as MSD outside the United States and Canada, recently announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), its flagship anti-PD-1 therapy, for the treatment of adult patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score

FDA Approval 40

FDA Approval Dermatology Regulation HR 40

Scienmag

JUNE 13, 2025

Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology in the University of Cincinnati’s Center for Advanced Structural Biology — potentially opening the door for better designed therapeutics. The research of a trio of UC structural biologists was published today in the Proceedings of the National Academy of Sciences ( PNAS ).

Research 98

Research Protein Life Science Regulation 98

Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Development 130

Development Antibody Clinical Trials Clinical Trials 130

The Pharma Data

JUNE 13, 2025

Mitsubishi Research Institute and Astellas Forge Collaborative Initiative to Support Japanese Drug Discovery Startups and Boost Global Innovation Mitsubishi Research Institute, Inc. (MRI) and Astellas Pharma Inc. (Astellas) today announced a significant new collaboration aimed at strengthening Japan’s role as a global hub for innovative drug discovery and fostering the growth of its biotechnology startups.

Research 40

Research Development Business Development Drugs 40

Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk

In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?

Compliance

Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

Research 239

Research Clinical Trials Clinical Trials Manufacturing 239

Pharma Marketing Network

JUNE 13, 2025

Artificial intelligence is rapidly transforming industries, and the pharmaceutical sector is no exception. When it comes to marketing strategies , AI is reshaping how pharma companies reach healthcare professionals (HCPs), engage patients, and optimize campaign performance. But what exactly does this mean for pharma marketers in 2025? Are we merely adding tools to the toolkit—or rewriting the entire playbook?

Marketing 52

Marketing Compliance Branding Engineer 52

The Pharma Data

JUNE 13, 2025

Elanco’s Zenrelia (ilunocitinib) Wins Positive CVMP Opinion, Paving the Way for EU Approval and Market Release Elanco Animal Health Incorporated (NYSE: ELAN) today announces a significant milestone in its ongoing expansion into veterinary care: the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has issued a positive opinion for Zenrelia™ (ilunocitinib).

Marketing 40

Marketing Dermatology Regulation Packaging 40

Drug Patent Watch

JUNE 13, 2025

"The Hiring Spree You Didn't See Coming: 3 Industries Where Clinical Trials Are Fueling a Surge in Legal Support As the pharmaceutical industry continues to navigate a complex landscape of patent expirations and emerging treatments, a new trend is emerging: companies are hiring lawyers at an unprecedented rate to protect their interests in the face of clinical trial data.

Clinical Trials 57

Clinical Trials Clinical Trials Trials Marketing 57

Advertisement

Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.

Life Science

The Pharma Data

JUNE 13, 2025

Amgen and Barry Sanders Raise Awareness About “Bad Cholesterol” in Documentary Highlighting Cardiovascular Disease Crisis in America Amgen today announced the launch of The Making of a Heart Attack , a powerful documentary that aims to illuminate the growing cardiovascular disease crisis in the United States — a condition that strikes someone nearly every 40 seconds with a heart attack or stroke.

Doctor 40

Doctor Doctors Research 40

XTalks

JUNE 13, 2025

The FDA has approved Merck’s Enflonsia (clesrovimab-cfor), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. The once-per-season injection offers a new option to safeguard infants from RSV-related illness, a major cause of pediatric hospitalizations in the US.

Antibody 52

Antibody Trials Production Marketing 52

Drug Channels

JUNE 13, 2025

Today’s guest post comes from Sean Wagner, VP of Client Partnerships and Carolyn Zele, Advisor, Solution Consulting at MMIT. Sean and Carolyn argue that planning for a successful drug launch must begin early—often well before Phase III. In this article, they present a six-step framework to help manufacturers align clinical development with payer expectations, patient needs, and real-world access dynamics.

Clinical Development 52

Clinical Development Manufacturing Development Drugs 52

pharmaphorum

JUNE 13, 2025

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by the pharma industry.

66

66

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

BioTech 365

JUNE 13, 2025

City of Hope Developed a Foundational Map of Tumor Cells for Personalized Brain Cancer Treatments City of Hope Developed a Foundational Map of Tumor Cells for Personalized Brain Cancer Treatments Scientists developed a new framework to improve the ability of … Continue reading →

Development 52

Development Scientist 52

pharmaphorum

JUNE 13, 2025

Treating primary bone cancer: The potential of listeria-based bioengineered bacterial immunotherapy Nicole.

52

52

BioTech 365

JUNE 13, 2025

Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms Partnership further validates Ethris’ novel technology platform based on stabilized … Continue reading →

52

52

Pfizer

JUNE 13, 2025

Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer skaarj Fri, 06/13/2025 - 16:20 Pfizer Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer Friday, June 13, 2025 - 04:23pm Share New York, June 13, 2025 – Pfizer Inc.

Gene 40

Gene DNA Trials Vaccination 40

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

STAT News

JUNE 13, 2025

Facing billions of dollars in proposed cuts to research overhead payments from the Trump administration, a coalition of academic groups has devised plans it believes could be more sensible, measured ways to revamp how the federal government pays for scientific research. STAT obtained a copy of the proposals, which were developed by the Joint Associations Group, or JAG, a collection of 10 organizations that represent universities, medical centers, and other research institutions.

Research 135

Research Development Scientist 135

Pharmaceutical Commerce

JUNE 13, 2025

As the rising cost of prescription medications in the United States becomes an increasing barrier for millions of people, how can we effectively address and improve patient adherence?

52

52

BioTech 365

JUNE 13, 2025

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing … Continue reading →

Life Science 52

Life Science Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

JUNE 13, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh

FDA Approval 130

FDA Approval Vaccine Vaccination Clinical Trials 130

Advertisement

Clinical Supply